Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT00005960
What this trial is testing

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
PainProstate Cancer
Amgen
Testing effectiveness (Phase 2)Study completedNCT00323882
What this trial is testing

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate CancerNeoplasm Metastasis
Bristol-Myers Squibb 75
Testing effectiveness (Phase 2)WithdrawnNCT03173859
What this trial is testing

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
University of Athens
Testing effectiveness (Phase 2)Study completedNCT00257478
What this trial is testing

The Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Who this might be right for
Prostate CancerCancer of ProstateProstatic Cancer+1 more
Astellas Pharma Inc
Early research (Phase 1)Study completedNCT03569280
What this trial is testing

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Who this might be right for
Castration-Resistant Prostate Cancer
Kangpu Biopharmaceuticals, Ltd. 16
Testing effectiveness (Phase 2)Ended earlyNCT00176527
What this trial is testing

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
University of Medicine and Dentistry of New Jersey 40
Testing effectiveness (Phase 2)Study completedNCT01503229
What this trial is testing

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
University of Washington 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383079
What this trial is testing

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerMCRPCProstate Cancer
Peter MacCallum Cancer Centre, Australia 36
Testing effectiveness (Phase 2)Study completedNCT00251225
What this trial is testing

Imatinib and Docetaxel in Prostate Cancer

Who this might be right for
Prostate Cancer
Leonard Appleman 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07592910
What this trial is testing

Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)
Prostate Cancer Clinical Trials Consortium 60
Testing effectiveness (Phase 2)Ended earlyNCT04918810
What this trial is testing

Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 6
Testing effectiveness (Phase 2)WithdrawnNCT01734681
What this trial is testing

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer.
GenSpera, Inc.
Testing effectiveness (Phase 2)Study completedNCT00411528
What this trial is testing

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Novartis Pharmaceuticals 185
Early research (Phase 1)Ended earlyNCT05037500
What this trial is testing

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+1 more
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)Study completedNCT00831467
What this trial is testing

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

Who this might be right for
Hormonal Refractory Prostate Cancer
CureVac 48
Early research (Phase 1)Study completedNCT00663832
What this trial is testing

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)UnknownNCT04188587
What this trial is testing

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Nanjing First Hospital, Nanjing Medical University 30
Testing effectiveness (Phase 2)Study completedNCT02494921
What this trial is testing

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Who this might be right for
Prostate Cancer
Rahul Aggarwal 43
Early research (Phase 1)Study completedNCT01646684
What this trial is testing

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 9
Not applicableUnknownNCT03381326
What this trial is testing

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

Who this might be right for
Prostate CancerMetastatic CancerCastration-resistant Prostate Cancer+1 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 104
Next Page